A new clinical trial involving ecnoglutide was registered on November 10, 2026. The study, titled "A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity," is listed under identifier NCT07929298.
The trial is a Phase 2 study. Its current status is not yet recruiting, meaning participant enrollment has not begun as of the listed date.
The study will evaluate ecnoglutide in tablet form among Chinese participants who have overweight or obesity. No results, efficacy data, or safety findings have been posted for this trial at this time. Ecnoglutide remains an unapproved compound under research and has not received regulatory approval for any indication.
Further details about the trial design, eligibility criteria, and timeline may become available as the study progresses toward recruitment. Readers can monitor the official clinical trial registry listing for updates on enrollment status and future results postings.
For more background on this compound, see the linked compound overview.